EPHOS-B Trial

Effect of Perioperative AntiHER-2 Therapy on Early Breast Cancer Study – Biological Phase (EPHOS-B). The EPHOS-B trial is a multicentre, three group, randomised controlled trial conducted in two parts. Part 1 (protocol versions 1 to 4): HER2+ patients were allocated in a 1:2:2 ratio to control, perioperative trastuzumab only or perioperative lapatinib only. This part of the trial will be superseded by Part 2 following the approval of amendment 5 by West Midlands - Edgbaston NRES Committee on 15/05/2013 and subsequently in each centre. Part 2 (Implemented from protocol version 5): HER2+ patients are allocated in a 1:1:2 ratio to control, perioperative trastuzumab only or the combination of lapatinib and trastuzumab. This part is now active.

Networks

  • ICR Clinical Trials & Statistics Unit (ICR-CTSU)

Contact Information

Email:
ephos-b-icrctsu@icr.ac.uk
Address:

ICR-CTSU
The Institute of Cancer Research
15 Cotswold Road
Sutton
Surrey
SM2 5NG
England

Annual Statistics

Year Access Requests Received Access Requests Approved
Internal External Commercial Internal External Commercial
2015 N/A N/A N/A N/A N/A N/A
2016 N/A N/A N/A N/A N/A N/A
2017 N/A N/A N/A N/A N/A N/A
2018 N/A N/A N/A N/A N/A N/A
2019 N/A N/A N/A N/A N/A N/A
2020 N/A N/A N/A N/A N/A N/A
2021 N/A N/A N/A N/A N/A N/A
2022 N/A N/A N/A N/A N/A N/A
2023 N/A N/A N/A N/A N/A N/A
2024 N/A N/A N/A N/A N/A N/A